Skip to Content

Frequently Searched

Supported by

Perspectives: Published Editorials and Industry Updates

Welcome to Perspectives, our blog designed to keep members, oncology stakeholders, and anyone interested in enhancing the care experience for oncology patients informed on critical issues. You’ll hear from thought leaders and learn about the impact and benefits of medically integrated pharmacy, operational insights designed to support you in the day-to-day delivery of care, as well as timely industry issues facing oncology pharmacy professionals.

SORT

NCODA Announces Brand Updates, a New Website, and a Future of Innovation and Collaboration 

April 13, 2025
As an organization, NCODA has always been committed to supporting our members in advancing the medically integrated healthcare team and advancing patient care. Today, we are excited to share some important changes that strengthen that commitment and reflect our evolution and focus. We have grown tremendously and are introducing meaningful updates to our brand and our online presence at ncoda.org.  

Caring for Patients in Every Step of their Journey 

March 31, 2025
NCODA recently sat down with members of the pharmacy team at Hematology-Oncology Associates of Central New York (HOACNY) to discuss the advantages of a medically integrated practice in their experience.

High Tech, High Touch: The MIP Model at Texas Oncology 

March 31, 2025
As we look at the implementation and value of the medially integrated pharmacy (MIP) model and how members are making a difference in the future of oncology care, we recently spoke with Texas Oncology leaders Gury Doshi, MD, hematology and medical oncologist, and Neal Dave, PharmD, executive director of pharmacy operations, for their perspectives.

Accreditation Advantage or Burden?

March 28, 2025
This article explores the challenges of traditional accreditation and how NCODA’s Center of Excellence program offers a practical, patient-centered solution for oncology practices and partners.

Enhanced Clarity for Bispecific Therapies: A Call to Action

February 12, 2025
NCODA supports the NCCN’s push for clearer terminology in bispecific antibody therapies—like the use of “lymphocyte engagers”—to improve safety, streamline care, and guide oncology practices in managing unique adverse events.

Navigate Medicare with Confidence

February 12, 2025
NCODA, in collaboration with the PAN Foundation, is excited to introduce a new Medicare Resource designed to help patients, caregivers, and healthcare professionals navigate the significant Medicare changes taking effect in 2025.

Preserving Patient-Centric Oncology Care Amid Step Therapy Changes

February 6, 2025
Explore how payer responses to the Inflation Reduction Act—like implementing step therapy—may limit oncology patient access, burden providers, and undermine the act’s intent. NCODA advocates for protecting clinician autonomy, reducing administrative barriers, and keeping patient outcomes at the center of care.

OncolyticsToday: Cancer Predisposition Variants

April 1, 2024
This article explores how the discovery of numerous cancer-predisposing variants in healthy individuals—like the author’s own experience—doesn’t always signal cause for alarm. It highlights the importance of expert interpretation, genetic counseling, and a deeper understanding of variant significance in the evolving landscape of genomic medicine.